ProPhase Labs, Inc. (PRPH)
PRPH is quoted over the counter, not listed on an exchange. ProPhase Labs, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | PRPH, quoted over the counter |
| SEC CIK | 0000868278 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | New York, NY |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued." | 10-Q 2026-08-19 |
| Cash and burn | $20K cash; operating cash flow -$1.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 15,592,556 (2026-08-17); 41,541,205 a year earlier; 16,845,029 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-08-17 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-12-22 | Source 2025-12-22 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-29 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-02 |
| Delisting | 25-NSE filed | 25-NSE 2026-01-23 |
| Auditor | Fruci & Associates II, PLLC, Spokane, Washington, United States | PCAOB Form AP 2026-06-14 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $1.0M | -$3.1M | -$78K | $20K | $438K | $3.8M | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | $1.2M | -$5.2M | -$748K | $31K | $304K | $4.1M | 10-Q/A 2026-07-09 |
| Q4 2025 2025-12-31 | $784K | -$7.4M | -$1.2M | $90K | $244K | $4.3M | 10-K 2026-06-01 |
| Q3 2025 2025-09-30 | $883K | -$6.8M | -$3.5M | $405K | $517K | $5.1M | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | $1.2M | -$4.5M | -$247K | $169K | No debt tags | $5.6M | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | $1.4M | $4.0M | -$3.4M | $88K | $2.5M | $5.8M | 10-Q/A 2026-07-09 |
| Q4 2024 2024-12-31 | $1.5M | -$34.4M | -$3.5M | $678K | $3.2M | $6.8M | 10-K 2026-06-01 |
| Q3 2024 2024-09-30 | $1.4M | -$6.6M | -$4.0M | $501K | $2.7M | -$625K | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-29 |
| Latest annual report | 10-K | 2026-06-01 |
| Latest quarterly / interim | 10-Q | 2026-08-19 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEF 14A | 2025-10-31 |
Source: SEC EDGAR submissions feed, 924 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier